MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

Search

United Therapeutics Corp

Gesloten

SectorGezondheidszorg

292.89 -1.47

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

291.72

Max

298.86

Belangrijke statistieken

By Trading Economics

Inkomsten

21M

322M

Verkoop

59M

794M

K/W

Sectorgemiddelde

11.573

39.564

EPS

6.63

Winstmarge

40.559

Werknemers

1,305

EBITDA

-41M

383M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+27.9% upside

Dividenden

By Dow Jones

Volgende Winsten

30 jul 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-4B

13B

Vorige openingsprijs

294.36

Vorige sluitingsprijs

292.89

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

United Therapeutics Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

7 okt 2024, 15:14 UTC

Belangrijke Marktbewegers

Liquidia Shares Rise After Supreme Court Rejects United Therapeutics' Patent Appeal

28 jan 2025, 10:30 UTC

Top Nieuws

Drug Companies Raise Prices on More Than 800 Drugs in January -- WSJ

Peer Vergelijking

Prijswijziging

United Therapeutics Corp Prognose

Koersdoel

By TipRanks

27.9% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 380.73 USD  27.9%

Hoogste 510 USD

Laagste 314 USD

Gebaseerd op 12 Wall Street-analisten die 12-maands prijsdoelen bieden voor United Therapeutics Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

12 ratings

9

Buy

3

Hold

0

Sell

Technische score

By Trading Central

292.345 / 309.245Steun & Weerstand

Korte Termijn

Weak Bullish Evidence

Gemiddeld Termijn

Weak Bullish Evidence

Lange Termijn

Bearish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over United Therapeutics Corp

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.